StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Investment analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Wednesday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 5.4 %

NYSE BTX opened at $0.29 on Wednesday. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The company has a fifty day simple moving average of $0.59 and a two-hundred day simple moving average of $1.24. The stock has a market cap of $17.29 million, a P/E ratio of -0.13 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.